tert-butyl 2-(tert-butyl)-3-oxo-2,3,6,9-tetrahydroisothiazolo[4,5-h]isoquinoline-8(7H)-carboxylate 1,1-dioxide | 1193523-42-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: tert-butyl 2-(tert-butyl)-3-oxo-2,3,6,9-tetrahydroisothiazolo[4,5-h]isoquinoline-8(7H)-carboxylate 1,1-dioxide
• CAS: 1193523-42-0
• 化学式: C₁₉H₂₆N₂O₅S
• 分子量: 394.492
• InChiKey: BRQJGRLJQYTQJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.92
• 重原子数：
  27.0
• 可旋转键数：
  0.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  83.99
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-(tert-butyl)-3-oxo-2,3,6,9-tetrahydroisothiazolo[4,5-h]isoquinoline-8(7H)-carboxylate 1,1-dioxide 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以100%的产率得到
  参考文献：
  名称：

  Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: Structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides

  摘要：

  A series of benzo[d]isothiazole-1,1-dioxides were designed and evaluated as inhibitors of HCV polymerase NS5B. Structure-based design led to the incorporation of a high affinity methyl sulfonamide group. Structure-activity relationship (SAR) studies of this series revealed analogues with submicromolar potencies in the HCV replicon assay and moderate pharmacokinetic properties. SAR studies combined with structure based drug design focused on the sulfonamide region led to a novel and potent cyclic analogue. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.08.022
• 作为产物：
  描述：

  、 4-溴-2-叔丁基-1,1-二氧代-1,2-二氢异噻唑-3-酮 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以43%的产率得到tert-butyl 2-(tert-butyl)-3-oxo-2,3,6,9-tetrahydroisothiazolo[4,5-h]isoquinoline-8(7H)-carboxylate 1,1-dioxide
  参考文献：
  名称：

  Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: Structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides

  摘要：

  A series of benzo[d]isothiazole-1,1-dioxides were designed and evaluated as inhibitors of HCV polymerase NS5B. Structure-based design led to the incorporation of a high affinity methyl sulfonamide group. Structure-activity relationship (SAR) studies of this series revealed analogues with submicromolar potencies in the HCV replicon assay and moderate pharmacokinetic properties. SAR studies combined with structure based drug design focused on the sulfonamide region led to a novel and potent cyclic analogue. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.08.022